Immunovant
New York, US · Founded 2018 · 282 employees on LinkedIn · 1 known investors
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
Founders & leadership
CV
Christopher Van TuylExecutive
MG
Michael GeffnerinChief Medical Officer2024–2025
PS
Pete SalzmanninCEO2019–2025
JS
Jay StoutinChief Technology Officer
MG
Melanie GloriainChief Operating Officer
ER
Eva Renee BarnettExecutive
BM
Bill MaciasExecutive
Board
EV
Eric VenkerBoard director
FT
Frank TortiBoard director
AF
Andrew FromkinBoard director
AP
Atul PandeBoard director
GM
George MigauskyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$450M disclosed across 1 round · 2025
▶$450MraisedJan 2025 · 11 investors · PharmaceuticalsRule 506(b)
▶$450MraisedJan 2025 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher Van TuylExecutive Officer
- Michael GeffnerExecutive Officer
- Andrew FromkinDirector
- Atul PandeDirector
- George MigauskyDirector
- Eric VenkerDirector
- Frank TortiDirector
- Pete SalzmannExecutive Officer, Director
- Jay StoutExecutive Officer
- Melanie GloriaExecutive Officer
- Eva Renee BarnettExecutive Officer
- Bill MaciasExecutive Officer
- Douglas HughesDirector
- Offering amount
- $450M
- Amount sold
- $450M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Signant Health34 shared keywordsSignant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.
Guardant Health32 shared keywordsGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Companies competing with Immunovant for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Immunovant do?
- Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
- Who are Immunovant's investors?
- Immunovant's investors include Altium Capital.
- How much funding has Immunovant raised?
- Immunovant has disclosed $450M raised across 1 round.
- Where is Immunovant headquartered?
- Immunovant is headquartered in New York, US.